HAE Logo

Haemonetics Corp (HAE) Stock Forecast & Price Prediction

Live HAE Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NYSE | Healthcare | Medical Instruments & Supplies

$62.36

+0.07 (0.11%)

12 Month Price Forecast For HAE

$62.36
Current Price
$3.14B
Market Cap
10 Ratings
Buy 8
Hold 1
Sell 1
Wall St Analyst Ratings

Distance to HAE Price Forecasts

+92.4%
To High Target of $120.00
+56.4%
To Median Target of $97.50
+9.0%
To Low Target of $68.00

HAE Price Momentum

+5.1%
1 Week Change
-16.9%
1 Month Change
-13.2%
1 Year Change
-20.5%
Year-to-Date Change
-36.3%
From 52W High of $97.97
+6.1%
From 52W Low of $58.80

๐Ÿค” Considering Haemonetics (HAE)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 15, 2025 3:24 AM UTC

HAE Analyst Ratings & Price Targets

Based on our analysis of 14 Wall Street analysts, HAE has a bullish consensus with a median price target of $97.50 (ranging from $68.00 to $120.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $62.36, the median forecast implies a 56.4% upside. This outlook is supported by 8 Buy, 1 Hold, and 1 Sell ratings.

The most optimistic forecast comes from Andrew Cooper at Raymond James, projecting a 92.4% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

HAE Analyst Consensus

8
Buy
1
Hold
1
Sell

HAE Price Target Range

Low
$68.00
Average
$97.50
High
$120.00
Current: $62.36

Latest HAE Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for HAE.

Date Firm Analyst Rating Change Price Target
Feb 7, 2025 Barrington Research Michael Petusky Outperform Maintains $95.00
Feb 7, 2025 Needham Mike Matson Buy Maintains $108.00
Feb 7, 2025 JMP Securities David Turkaly Market Outperform Maintains $100.00
Feb 7, 2025 Raymond James Andrew Cooper Strong Buy Reiterates $115.00
Dec 6, 2024 JP Morgan Rohin Patel Overweight Initiates $116.00
Dec 4, 2024 Barrington Research Michael Petusky Outperform Maintains $108.00
Dec 3, 2024 Needham Mike Matson Buy Reiterates $112.00
Nov 15, 2024 Needham Mike Matson Buy Reiterates $112.00
Nov 8, 2024 Raymond James Andrew Cooper Strong Buy Upgrade $120.00
Nov 8, 2024 Barrington Research Michael Petusky Outperform Maintains $108.00
Sep 23, 2024 Barrington Research Michael Petusky Outperform Maintains $108.00
Sep 13, 2024 CL King Kristen Stewart Buy Initiates $116.00
Sep 11, 2024 B of A Securities Craig Bijou Neutral Initiates $85.00
Sep 10, 2024 BTIG Marie Thibault Buy Initiates $112.00
Aug 22, 2024 Citigroup Joanne Wuensch Neutral Maintains $85.00
Aug 13, 2024 JMP Securities David Turkaly Market Outperform Reiterates $125.00
Aug 9, 2024 Barrington Research Michael Petusky Outperform Maintains $108.00
Jun 12, 2024 Needham Mike Matson Buy Upgrade $112.00
May 10, 2024 JMP Securities David Turkaly Market Outperform Maintains $125.00
May 10, 2024 Barrington Research Michael Petusky Outperform Maintains $107.00

Stocks Similar to Haemonetics Corp

The following stocks are similar to Haemonetics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Haemonetics Corp (HAE) Financial Data

Haemonetics Corp has a market capitalization of $3.14B with a P/E ratio of 24.6x. The company generates $1.36B in trailing twelve-month revenue with a 9.1% profit margin.

Revenue growth is +8.6% quarter-over-quarter, while maintaining an operating margin of +16.4% and return on equity of +14.0%.

Valuation Metrics

Market Cap $3.14B
Enterprise Value $4.59B
P/E Ratio 24.6x
PEG Ratio 11.7x
Price/Sales 2.3x

Growth & Margins

Revenue Growth (YoY) +8.6%
Gross Margin +55.5%
Operating Margin +16.4%
Net Margin +9.1%
EPS Growth +35.8%

Financial Health

Cash/Price Ratio +9.6%
Current Ratio 3.5x
Debt/Equity 149.6x
ROE +14.0%
ROA +5.9%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Haemonetics Corp logo

Haemonetics Corp (HAE) Company Overview

About Haemonetics Corp

What They Do

Provides medical products and solutions for blood management.

Business Model

The company generates revenue by selling a range of medical products, including automated plasma collection systems, blood component collection systems, and donor management software. Its business model relies on direct sales, independent distributors, and sales representatives to reach various healthcare providers and organizations, ensuring efficient blood and plasma management.

Additional Information

Founded in 1971 and headquartered in Boston, Massachusetts, the company focuses on innovative technologies that enhance donor and patient care. Its products are essential for hospitals and blood banks, positioning the company as a key player in the healthcare sector, particularly in blood management and transfusion solutions.

Company Information

Sector

Healthcare

Industry

Medical Instruments & Supplies

Employees

3,657

CEO

Mr. Christopher A. Simon

Country

United States

IPO Year

1991

Haemonetics Corp (HAE) Latest News & Analysis

HAE stock latest news image
Quick Summary

Haemonetics Corporation (NYSE:HAE) will hold its Q3 2025 Earnings Conference Call on February 6, 2025, at 8:30 AM ET, featuring key executives and financial analysts.

Why It Matters

The earnings conference call provides insights into Haemonetics' financial performance and strategic direction, which can influence stock valuation and investor sentiment.

Source: Seeking Alpha
Market Sentiment: Neutral
HAE stock latest news image
Quick Summary

Haemonetics Corporation (NYSE: HAE) released its Q3 fiscal year 2025 financial results, ending December 28, 2024. A conference call will be held at 8:00 a.m. for discussion and Q&A.

Why It Matters

Haemonetics' Q3 fiscal results and upcoming conference call may impact stock performance, providing insights into financial health and guidance for future growth.

Source: PRNewsWire
Market Sentiment: Neutral
HAE stock latest news image
Quick Summary

Haemonetics (HAE) reported Q2 earnings of $1.19 per share, matching the Zacks Consensus Estimate and up from $1.04 per share year-over-year.

Why It Matters

Haemonetics' earnings match expectations and show year-over-year growth, indicating stability and potential for future profitability, which can influence investor confidence and stock performance.

Source: Zacks Investment Research
Market Sentiment: Positive
HAE stock latest news image
Quick Summary

Haemonetics (HAE) reported its revenue and EPS for Q4 2024, highlighting performance against Wall Street estimates and year-ago figures.

Why It Matters

Comparing Haemonetics' revenue and EPS to Wall Street estimates and year-ago figures indicates market performance, potential growth, and investment viability.

Source: Zacks Investment Research
Market Sentiment: Positive
HAE stock latest news image
Quick Summary

Haemonetics reported strong third-quarter fiscal 2025 results, showing significant earnings growth and margin expansion, attributed to its long-range strategic plan.

Why It Matters

Haemonetics' strong earnings growth and margin expansion signal effective long-term strategies, potentially boosting investor confidence and driving stock performance.

Source: Zacks Investment Research
Market Sentiment: Positive
HAE stock latest news image
Quick Summary

Zacks Style Scores can help investors identify strong, market-beating stocks for their portfolios.

Why It Matters

The Zacks Style Scores can guide investors in identifying high-potential stocks, enhancing portfolio performance and potentially leading to better returns.

Source: Zacks Investment Research
Market Sentiment: Positive

Frequently Asked Questions About HAE Stock

What is Haemonetics Corp's (HAE) stock forecast for 2025?

Based on our analysis of 14 Wall Street analysts, Haemonetics Corp (HAE) has a median price target of $97.50. The highest price target is $120.00 and the lowest is $68.00.

Is HAE stock a good investment in 2025?

According to current analyst ratings, HAE has 8 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $62.36. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for HAE stock?

Wall Street analysts predict HAE stock could reach $97.50 in the next 12 months. This represents a 56.4% increase from the current price of $62.36. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Haemonetics Corp's business model?

The company generates revenue by selling a range of medical products, including automated plasma collection systems, blood component collection systems, and donor management software. Its business model relies on direct sales, independent distributors, and sales representatives to reach various healthcare providers and organizations, ensuring efficient blood and plasma management.

What is the highest forecasted price for HAE Haemonetics Corp?

The highest price target for HAE is $120.00 from Andrew Cooper at Raymond James, which represents a 92.4% increase from the current price of $62.36.

What is the lowest forecasted price for HAE Haemonetics Corp?

The lowest price target for HAE is $68.00 from at , which represents a 9.0% increase from the current price of $62.36.

What is the overall HAE consensus from analysts for Haemonetics Corp?

The overall analyst consensus for HAE is bullish. Out of 14 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $97.50.

How accurate are HAE stock price projections?

Stock price projections, including those for Haemonetics Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.